Norovirus vaccine against experimental human GII.4 virus illness: A challenge study in healthy adults

Journal of Infectious Diseases

Volumn 211, Issue 6, 2015, Pages 870-878

  Bernstein, David I ^a   Atmar, Robert L ^b   Lyon, G Marshall ^c   Treanor, John J ^d   Chen, Wilbur H ^e   Jiang, Xi ^a   Vinjé, Jan ^f   Gregoricus, Nicole ^f   Frenck, Robert W ^a   Moe, Christine L ^g   Al Ibrahim, Mohamed S ^h   Barrett, Jill ⁱ   Ferreira, Jennifer ⁱ   Estes, Mary K ^b   Graham, David Y ^b   Goodwin, Robert ^j   Borkowski, Astrid ^k   Clemens, Ralf ^k   Mendelman, Paul M ^j  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g EMORY UNIVERSITY   (United States)

^h Shin Nippon Biomedical Laboratories (SNBL) Clinical Pharmacology Center   (United States)

ⁱ EMMES CORPORATION   (United States)

^j Takeda Vaccines   (United States)

^k Takeda Pharmaceuticals International GmbH   (Switzerland)

more..

Author keywords

acute gastroenteritis; challenge; norovirus; vaccine

Indexed keywords

ALUMINUM HYDROXIDE; NOROVIRUS VACCINE; PHOSPHORYL LIPID A; PLACEBO; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LIPID A;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXPERIMENTAL INFECTION; FEVER; HEADACHE; HOSPITAL PATIENT; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; MALAISE; MALE; MYALGIA; NAUSEA; NOROVIRUS; NOROVIRUS INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELF REPORT; VACCINATION; VIRUS LIKE AGENT; VIRUS SHEDDING; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; CALICIVIRIDAE INFECTIONS; CLINICAL TRIAL; FEMALE; GASTROENTERITIS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CALICIVIRIDAE INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; GASTROENTERITIS; HUMANS; LIPID A; MALE; MIDDLE AGED; NOROVIRUS; VACCINATION; VIRAL LOAD; VIRAL VACCINES; YOUNG ADULT;

EID: 84924352540     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu497     Document Type: Article

References (25)

1. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009; 361:1776-85
2. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011; 17:7-15
3. Centers for Disease Control and Prevention. Norovirus. http://www.cdc. gov/norovirus/trends-outbreaks.html. Accessed 24 April 2014
4. Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121-30
5. Green KY. Caliciviridae: the noroviruses. In: Knipe DM, Howley P, eds. Fields virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2013, 582-608
6. Richardson C, Bargatze RF, Goodwin R, Mendelman PM. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Exp Rev Vaccines 2013; 12:155-67
7. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999; 117:40-8
8. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-7
9. Treanor JJ, Atmar RL, Frey SE, et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis 2014; 210:1763-71
10. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649-58
11. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365:2178-87
12. Parra GI, Bok K, Taylor R, et al. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012; 30:3580-6
13. Mai H, Jin M, Guo X, et al. Clinical and epidemiologic characteristics of norovirus GII.4 Sydney during winter 2012-13 in Beijing, China following its global emergence. PLoS One 2013; 8:e71483
14. Hoa Tran TN, Trainor E, Nakagomi T, Cunliffe NA, Nakagomi O. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global distribution of genogroups, genotypes and GII.4 variants. J Clin Virol 2013; 56:185-93
15. Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012; 8:e1002705
16. Desai R, Hembree CD, Handel A, et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin Infect Dis 2012; 55:189-93
17. Noel JS, Ando T, Leite JP, et al. Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995. J Med Virol 1997; 53:372-83
18. Frenck R, Bernstein DI, XiaM, et al. Predicting susceptibility to norovirus GII.4 using a human challenge model. J Infect Dis 2012; 206:1386-93
19. Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003; 188:19-31
20. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002; 122:1967-77
21. Yang Y, Xia M, TanM, et al. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol 2010; 84:9595-607
22. Vesikari T. Rotavirus vaccination: a concise review. Clin Microbiol Infect 2012; 18(suppl 5):57-63
23. Atmar RL, Estes MK. Norovirus vaccine development: next steps. Exp Rev Vacc 2012; 11:1023-5
24. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis 2013; 19:1260-7
25. Lindesmith LC, Donaldson E, Leon J, et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 2010; 84:1800-15